Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury.
about
Bridging Translation by Improving Preclinical Study Design in AKIRecent advances in renal hypoxia: insights from bench experiments and computer simulations.Mechanisms of fibrosis in acute liver failure.Hypoxia in diabetic kidneys.Hypoxia as a key player in the AKI-to-CKD transition.Bidirectional signalling between EphA2 and ephrinA1 increases tubular cell attachment, laminin secretion and modulates erythropoietin expression after renal hypoxic injury.Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension.Erythropoietin-enhanced endothelial progenitor cell recruitment in peripheral blood and renal vessels during experimental acute kidney injury in rats.Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.Mitochondria Protection after Acute Ischemia Prevents Prolonged Upregulation of IL-1β and IL-18 and Arrests CKD.Effects of Erythropoietin Receptor Activity on Angiogenesis, Tubular Injury and Fibrosis in Acute Kidney Injury: A "U-Shaped" Relationship.Renal hypoxia in kidney disease: Cause or consequence?Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival.Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.Optical properties of acute kidney injury measured by quantitative phase imaging.
P2860
Q28084530-4499AF96-66B7-471E-9E25-FF47783372DAQ37139470-785D6308-4F5F-419E-AD85-C16740918E92Q37257361-B02373B6-69B4-4DA1-BA20-7C19BE3439B9Q38233058-87A6F940-6D00-4D48-8129-0409CD881772Q38263324-BC029B2B-0261-461C-832B-9AB3AC1D302DQ38768279-D431A85C-D51B-4336-840E-C009845F2B83Q39266683-C92FE308-B01B-478A-91E8-6746D7751382Q41089824-32680E45-53EF-4645-985C-C56EFBDFE75EQ42722918-80F8ECDA-3226-4D25-8746-197A0680328FQ46455327-D89D5C33-CF4B-43B5-9891-1F6D519C0AF6Q49541601-CA938D8A-F209-4482-9030-620F79F38B2FQ49842384-8040CBEC-B321-4A0A-93D2-D2A72FAEAF3BQ51095965-F2542CEF-3228-4FEB-9561-37CA020F3FF7Q51546144-76FF6DC4-FDAF-464B-BF2C-025A4014BFCFQ52655001-55281DA8-F368-4CD3-B54D-0DDFD3C05864
P2860
Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Increased progression to kidne ...... tment for acute kidney injury.
@en
Increased progression to kidne ...... tment for acute kidney injury.
@nl
type
label
Increased progression to kidne ...... tment for acute kidney injury.
@en
Increased progression to kidne ...... tment for acute kidney injury.
@nl
prefLabel
Increased progression to kidne ...... tment for acute kidney injury.
@en
Increased progression to kidne ...... tment for acute kidney injury.
@nl
P2093
P2860
P1476
Increased progression to kidne ...... tment for acute kidney injury.
@en
P2093
David W Johnson
Glenda C Gobe
Lindsay Brown
Malcolm West
Nigel C Bennett
P2860
P304
P356
10.1152/AJPRENAL.00241.2013
P577
2014-01-08T00:00:00Z